Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...

Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery. Treatment with emactuzumab has received fast ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...

Biologists have discovered that disruptions in transfer RNA function can lead to the development of cleft lip and cleft palate.

Cleft lip and cleft palate are among the most common birth defects, occurring in about one in 1,050 births in the United ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

Cleft lip and cleft palate are among the most common birth defects, occurring in about one in 1,050 births in the United States.

Sam's Club, an American warehouse supermarket chain owned by U.S. retail giant Walmart, is investigating claims of a Clop ransomware breach. The Walmart division operates over 600 warehouse ...